SG3 Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

SG3 Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,975	Closed	-$506K	–	1172
2021 Q4	$506K	Buy	+3,975	New	+$522K	0.01%	620
2021 Q3	–	Sell	-56,402	Closed	-$10M	–	1120
2021 Q2	$10M	Sell	56,402 -8,598	-13%	-$1.49M	0.36%	57
2021 Q1	$10.7M	Buy	65,000 +62,225	+2,242%	+$10.2M	0.27%	81
2020 Q4	$458K	Buy	+2,775	New	+$413K	0.01%	747
2017 Q2	–	Sell	-3,000	Closed	-$435K	–	258
2017 Q1	$435K	Buy	+3,000	New	+$391K	0.08%	146

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

SG3 Management's JAZZ Position: Q1 2022 in Review

SG3 Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 3,975 shares — an estimated $506K sold.

SG3 Management first reported a position in JAZZ in Q1 2017 and held it in 5 quarters. The position peaked at $10.7M in Q1 2021. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

SG3 Management reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 3,975 Jazz Pharmaceuticals shares in Q1 2022, an estimated $506K.
SG3 Management first reported a position in Jazz Pharmaceuticals in Q1 2017 and held it in 5 quarters.
SG3 Management's Jazz Pharmaceuticals position peaked at $10.7M in Q1 2021.
462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.